Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C10H15NO |
Molecular Weight | 165.2326 |
Optical Activity | ( + ) |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@]([H])([C@]([H])(c1ccccc1)O)NC
InChI
InChIKey=KWGRBVOPPLSCSI-WCBMZHEXSA-N
InChI=1S/C10H15NO/c1-8(11-2)10(12)9-6-4-3-5-7-9/h3-8,10-12H,1-2H3/t8-,10+/m0/s1
Molecular Formula | C10H15NO |
Molecular Weight | 165.2326 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.drugs.com/pseudoephedrine.htmlCurator's Comment:: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/12373557 | http://www.mayoclinic.org/drugs-supplements/ephedra--ma-huang/background/hrb-20059270 | https://www.sudafed.com/adult-products/congestion/sudafed-24-hour#uses-and-directions | https://www.ncbi.nlm.nih.gov/pubmedhealth/PMHT0011888 | https://www.ncbi.nlm.nih.gov/pubmed/11772135 | https://www.ncbi.nlm.nih.gov/pubmed/10449190 | https://www.ncbi.nlm.nih.gov/pubmed/12954796
Sources: https://www.drugs.com/pseudoephedrine.html
Curator's Comment:: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/12373557 | http://www.mayoclinic.org/drugs-supplements/ephedra--ma-huang/background/hrb-20059270 | https://www.sudafed.com/adult-products/congestion/sudafed-24-hour#uses-and-directions | https://www.ncbi.nlm.nih.gov/pubmedhealth/PMHT0011888 | https://www.ncbi.nlm.nih.gov/pubmed/11772135 | https://www.ncbi.nlm.nih.gov/pubmed/10449190 | https://www.ncbi.nlm.nih.gov/pubmed/12954796
Pseudoephedrine is a sympathomimetic drug. Pseudoephedrine acts as an adrenomimetic and inhibitor of monoamine transporters. Ephedra sinica, a species of ephedra (ma huang), contains ephedrine and pseudoephedrine. Ephedra has been found to stimulate the nervous system, increase airflow into the lungs and constrict blood vessels. In combination with caffeine, ephedra appears to cause weight loss. Pseudoephedrine is a decongestant that shrinks blood vessels in the nasal passages. Pseudoephedrine is used to relieve nasal or sinus congestion caused by the common cold, sinusitis, and hay fever and other respiratory allergies.
Originator
Sources: A. Ladenburg, C. Oelschlägel, Ber. 22, 1823 (1889).
Curator's Comment:: (+)-threo-isomer of ephedrine, q.v. Isoln from E. vulgaris: A. Ladenburg, C. Oelschlägel, Ber. 22, 1823 (1889). Synthesis: E. Späth, R. Göhring, Monatsh. Chem. 41, 319 (1920). reference retrieved from http://www.drugfuture.com/chemdata/pseudoephedrine.html
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL238 |
5.6 µM [IC50] | ||
Target ID: CHEMBL222 |
1.18 µM [IC50] | ||
Target ID: CHEMBL2095203 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12954796 |
|||
Target ID: CHEMBL2094118 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10449190 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | SUDAFED 24 HOUR Approved Usetemporarily relieves nasal congestion due to the common cold, hay fever or other upper respiratory allergies; reduces swelling of nasal passages; relieves sinus pressure Launch Date7.2429122E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
292 ng/mL |
120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered: |
PSEUDOEPHEDRINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4346 ng × h/mL |
120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered: |
PSEUDOEPHEDRINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6.3 h |
120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered: |
PSEUDOEPHEDRINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
1500 mg single, oral Overdose |
unknown, 16 years n = 1 Health Status: unknown Age Group: 16 years Sex: F Population Size: 1 Sources: |
Other AEs: Rhabdomyolysis, Creatine kinase increased... Other AEs: Rhabdomyolysis (1 patient) Sources: Creatine kinase increased (1 patient) Blood myoglobin increased (1 patient) |
150 mg 2 times / day multiple, oral Highest studied dose Dose: 150 mg, 2 times / day Route: oral Route: multiple Dose: 150 mg, 2 times / day Sources: |
healthy, 24 years n = 17 Health Status: healthy Age Group: 24 years Sex: M Population Size: 17 Sources: |
Other AEs: Tension, Dry mouth... Other AEs: Tension (10 patients) Sources: Dry mouth (6 patients) Tachycardia (9 patients) Palpitations (10 patients) Anxiety (13 patients) Insomnia (12 patients) Anorexia (7 patients) Restlessness (10 patients) |
90 mg 1 times / day multiple, oral Overdose Dose: 90 mg, 1 times / day Route: oral Route: multiple Dose: 90 mg, 1 times / day Sources: |
unhealthy, 3 years n = 1 Health Status: unhealthy Age Group: 3 years Sex: M Population Size: 1 Sources: |
Disc. AE: Urinary retention... AEs leading to discontinuation/dose reduction: Urinary retention (acute, 1 patient) Sources: |
30 mg 2 times / day multiple, oral Dose: 30 mg, 2 times / day Route: oral Route: multiple Dose: 30 mg, 2 times / day Co-administed with:: acetominophen(500 mg twice daily, oral) Sources: |
unhealthy, 37 years n = 1 Health Status: unhealthy Condition: sinusitis Age Group: 37 years Sex: F Population Size: 1 Sources: |
Disc. AE: Ischemic colitis, Abdominal pain... AEs leading to discontinuation/dose reduction: Ischemic colitis (1 patient) Sources: Abdominal pain (acute, 1 patient) |
720 mg 1 times / day multiple, oral Highest studied dose Dose: 720 mg, 1 times / day Route: oral Route: multiple Dose: 720 mg, 1 times / day Sources: |
unhealthy, 38.8 years n = 38 Health Status: unhealthy Age Group: 38.8 years Sex: M+F Population Size: 38 Sources: |
|
30 mg 3 times / day multiple, oral Dose: 30 mg, 3 times / day Route: oral Route: multiple Dose: 30 mg, 3 times / day Sources: |
unhealthy, 44 years n = 1 Health Status: unhealthy Condition: upper airway infection Age Group: 44 years Sex: F Population Size: 1 Sources: |
Disc. AE: Ischemic colitis, Abdominal pain... AEs leading to discontinuation/dose reduction: Ischemic colitis (1 patient) Sources: Abdominal pain (acute, 1 patient) |
120 mg 1 times / day multiple, oral Dose: 120 mg, 1 times / day Route: oral Route: multiple Dose: 120 mg, 1 times / day Sources: |
unhealthy, 46 years n = 1 Health Status: unhealthy Condition: chronic sinusitis | allergic rhinitis Age Group: 46 years Sex: F Population Size: 1 Sources: |
Disc. AE: Ischemic colitis, Abdominal pain... AEs leading to discontinuation/dose reduction: Ischemic colitis (1 patient) Sources: Abdominal pain (acute, 1 patient) |
30 mg 2 times / day multiple, oral Dose: 30 mg, 2 times / day Route: oral Route: multiple Dose: 30 mg, 2 times / day Co-administed with:: acetominophen(500 mg twice daily, oral) Sources: chlorpheniramine maleate(2 mg; twice daily, oral) |
unhealthy, 50 years n = 1 Health Status: unhealthy Condition: rhinitis Age Group: 50 years Sex: F Population Size: 1 Sources: |
Disc. AE: Ischemic colitis, Abdominal pain... AEs leading to discontinuation/dose reduction: Ischemic colitis (1 patient) Sources: Abdominal pain (acute, 1 patient) |
720 mg single, oral Overdose |
unhealthy, 87 years n = 1 Health Status: unhealthy Age Group: 87 years Sex: M Population Size: 1 Sources: |
Other AEs: Hypertension... |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Blood myoglobin increased | 1 patient | 1500 mg single, oral Overdose |
unknown, 16 years n = 1 Health Status: unknown Age Group: 16 years Sex: F Population Size: 1 Sources: |
Creatine kinase increased | 1 patient | 1500 mg single, oral Overdose |
unknown, 16 years n = 1 Health Status: unknown Age Group: 16 years Sex: F Population Size: 1 Sources: |
Rhabdomyolysis | 1 patient | 1500 mg single, oral Overdose |
unknown, 16 years n = 1 Health Status: unknown Age Group: 16 years Sex: F Population Size: 1 Sources: |
Palpitations | 10 patients | 150 mg 2 times / day multiple, oral Highest studied dose Dose: 150 mg, 2 times / day Route: oral Route: multiple Dose: 150 mg, 2 times / day Sources: |
healthy, 24 years n = 17 Health Status: healthy Age Group: 24 years Sex: M Population Size: 17 Sources: |
Restlessness | 10 patients | 150 mg 2 times / day multiple, oral Highest studied dose Dose: 150 mg, 2 times / day Route: oral Route: multiple Dose: 150 mg, 2 times / day Sources: |
healthy, 24 years n = 17 Health Status: healthy Age Group: 24 years Sex: M Population Size: 17 Sources: |
Tension | 10 patients | 150 mg 2 times / day multiple, oral Highest studied dose Dose: 150 mg, 2 times / day Route: oral Route: multiple Dose: 150 mg, 2 times / day Sources: |
healthy, 24 years n = 17 Health Status: healthy Age Group: 24 years Sex: M Population Size: 17 Sources: |
Insomnia | 12 patients | 150 mg 2 times / day multiple, oral Highest studied dose Dose: 150 mg, 2 times / day Route: oral Route: multiple Dose: 150 mg, 2 times / day Sources: |
healthy, 24 years n = 17 Health Status: healthy Age Group: 24 years Sex: M Population Size: 17 Sources: |
Anxiety | 13 patients | 150 mg 2 times / day multiple, oral Highest studied dose Dose: 150 mg, 2 times / day Route: oral Route: multiple Dose: 150 mg, 2 times / day Sources: |
healthy, 24 years n = 17 Health Status: healthy Age Group: 24 years Sex: M Population Size: 17 Sources: |
Dry mouth | 6 patients | 150 mg 2 times / day multiple, oral Highest studied dose Dose: 150 mg, 2 times / day Route: oral Route: multiple Dose: 150 mg, 2 times / day Sources: |
healthy, 24 years n = 17 Health Status: healthy Age Group: 24 years Sex: M Population Size: 17 Sources: |
Anorexia | 7 patients | 150 mg 2 times / day multiple, oral Highest studied dose Dose: 150 mg, 2 times / day Route: oral Route: multiple Dose: 150 mg, 2 times / day Sources: |
healthy, 24 years n = 17 Health Status: healthy Age Group: 24 years Sex: M Population Size: 17 Sources: |
Tachycardia | 9 patients | 150 mg 2 times / day multiple, oral Highest studied dose Dose: 150 mg, 2 times / day Route: oral Route: multiple Dose: 150 mg, 2 times / day Sources: |
healthy, 24 years n = 17 Health Status: healthy Age Group: 24 years Sex: M Population Size: 17 Sources: |
Urinary retention | acute, 1 patient Disc. AE |
90 mg 1 times / day multiple, oral Overdose Dose: 90 mg, 1 times / day Route: oral Route: multiple Dose: 90 mg, 1 times / day Sources: |
unhealthy, 3 years n = 1 Health Status: unhealthy Age Group: 3 years Sex: M Population Size: 1 Sources: |
Ischemic colitis | 1 patient Disc. AE |
30 mg 2 times / day multiple, oral Dose: 30 mg, 2 times / day Route: oral Route: multiple Dose: 30 mg, 2 times / day Co-administed with:: acetominophen(500 mg twice daily, oral) Sources: |
unhealthy, 37 years n = 1 Health Status: unhealthy Condition: sinusitis Age Group: 37 years Sex: F Population Size: 1 Sources: |
Abdominal pain | acute, 1 patient Disc. AE |
30 mg 2 times / day multiple, oral Dose: 30 mg, 2 times / day Route: oral Route: multiple Dose: 30 mg, 2 times / day Co-administed with:: acetominophen(500 mg twice daily, oral) Sources: |
unhealthy, 37 years n = 1 Health Status: unhealthy Condition: sinusitis Age Group: 37 years Sex: F Population Size: 1 Sources: |
Ischemic colitis | 1 patient Disc. AE |
30 mg 3 times / day multiple, oral Dose: 30 mg, 3 times / day Route: oral Route: multiple Dose: 30 mg, 3 times / day Sources: |
unhealthy, 44 years n = 1 Health Status: unhealthy Condition: upper airway infection Age Group: 44 years Sex: F Population Size: 1 Sources: |
Abdominal pain | acute, 1 patient Disc. AE |
30 mg 3 times / day multiple, oral Dose: 30 mg, 3 times / day Route: oral Route: multiple Dose: 30 mg, 3 times / day Sources: |
unhealthy, 44 years n = 1 Health Status: unhealthy Condition: upper airway infection Age Group: 44 years Sex: F Population Size: 1 Sources: |
Ischemic colitis | 1 patient Disc. AE |
120 mg 1 times / day multiple, oral Dose: 120 mg, 1 times / day Route: oral Route: multiple Dose: 120 mg, 1 times / day Sources: |
unhealthy, 46 years n = 1 Health Status: unhealthy Condition: chronic sinusitis | allergic rhinitis Age Group: 46 years Sex: F Population Size: 1 Sources: |
Abdominal pain | acute, 1 patient Disc. AE |
120 mg 1 times / day multiple, oral Dose: 120 mg, 1 times / day Route: oral Route: multiple Dose: 120 mg, 1 times / day Sources: |
unhealthy, 46 years n = 1 Health Status: unhealthy Condition: chronic sinusitis | allergic rhinitis Age Group: 46 years Sex: F Population Size: 1 Sources: |
Ischemic colitis | 1 patient Disc. AE |
30 mg 2 times / day multiple, oral Dose: 30 mg, 2 times / day Route: oral Route: multiple Dose: 30 mg, 2 times / day Co-administed with:: acetominophen(500 mg twice daily, oral) Sources: chlorpheniramine maleate(2 mg; twice daily, oral) |
unhealthy, 50 years n = 1 Health Status: unhealthy Condition: rhinitis Age Group: 50 years Sex: F Population Size: 1 Sources: |
Abdominal pain | acute, 1 patient Disc. AE |
30 mg 2 times / day multiple, oral Dose: 30 mg, 2 times / day Route: oral Route: multiple Dose: 30 mg, 2 times / day Co-administed with:: acetominophen(500 mg twice daily, oral) Sources: chlorpheniramine maleate(2 mg; twice daily, oral) |
unhealthy, 50 years n = 1 Health Status: unhealthy Condition: rhinitis Age Group: 50 years Sex: F Population Size: 1 Sources: |
Hypertension | 1 patient | 720 mg single, oral Overdose |
unhealthy, 87 years n = 1 Health Status: unhealthy Age Group: 87 years Sex: M Population Size: 1 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Cetirizine/pseudoephedrine. | 2001 |
|
Ischaemic colitis on pseudoephedrine. | 2001 Aug |
|
Cost-effectiveness of urinary dipsticks to screen asymptomatic catheter-associated urinary infections in an intensive care unit. | 2001 Dec |
|
Stereocontrolled Mannich reaction with enolizable imines using (S,S)-(+)-pseudoephedrine as chiral auxiliary. Asymmetric synthesis of alpha,beta-disubstituted beta-aminoesters and beta-lactams. | 2001 Dec 28 |
|
Epinephrine analogues. | 2001 Nov |
|
Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. | 2001 Nov |
|
Chloroephedrine: contaminant of methamphetamine synthesis with cardiovascular activity. | 2001 Nov 1 |
|
Biotransformation of benzaldehyde into (R)-phenylacetylcarbinol by filamentous fungi or their extracts. | 2001 Oct |
|
Acute psychosis due to the interaction of legal compounds--ephedra alkaloids in 'vigueur fit' tablets, caffeine in 'red bull' and alcohol. | 2001 Oct |
|
Cathinone (Khat) and methcathinone (CAT) in urine specimens: a gas chromatographic-mass spectrometric detection procedure. | 2001 Oct |
|
Relationship between expansion of the CAG repeat in exon 1 of the androgen receptor gene and idiopathic male infertility. | 2001 Oct |
|
Small-cell carcinoma of the esophagus: report of three cases and review of the literature with emphasis on therapy. | 2001 Sep |
|
Community pharmacists' experience of over-the-counter medicine misuse in Scotland. | 2001 Sep |
|
Time-controlled release pseudoephedrine tablets: bioavailability and in vitro/in vivo correlations. | 2001 Sep |
|
Separation and determination of ephedrine alkaloids and tetramethylpyrazine in Ephedra sinica Stapf by gas chromatography-mass spectrometry. | 2001 Sep |
|
Toxicity of over-the-counter cough and cold medications. | 2001 Sep |
|
Rapid chiral on-chip separation with simplified amperometric detection. | 2001 Sep 14 |
|
Analysis of enantiomers giving partially overlapped peaks by using different treatments of the chromatographic ultraviolet signals: quantification of pseudoephedrine enantiomers. | 2001 Sep 28 |
|
Liquid chromatography/tandem mass spectrometric bioanalysis using normal-phase columns with aqueous/organic mobile phases - a novel approach of eliminating evaporation and reconstitution steps in 96-well SPE. | 2002 |
|
Generalized dermatitis due to pseudoephedrine. | 2002 Aug |
|
Linezolid: its role in the treatment of gram-positive, drug-resistant bacterial infections. | 2002 Feb 15 |
|
Pseudoephedrine causing mania-like symptoms. | 2002 Feb 22 |
|
Immediate hypersensitivity due to pseudoephedrine. | 2002 Jan |
|
Maternal medication use and risks of gastroschisis and small intestinal atresia. | 2002 Jan 1 |
|
Cerebral vasoconstriction and stroke after use of serotonergic drugs. | 2002 Jan 8 |
|
Pharmacological characterization of a noninvasive, chronic, experimental dog model of nasal congestion. | 2002 Jan-Feb |
|
Acoustic rhinometry in the dog: a novel large animal model for studies of nasal congestion. | 2002 Jan-Feb |
|
Onset of action, efficacy, and safety of fexofenadine 60 mg/pseudoephedrine 120 mg versus placebo in the Atlanta allergen exposure unit. | 2002 Jul |
|
Pharmacology of ephedra alkaloids and caffeine after single-dose dietary supplement use. | 2002 Jun |
|
Oral medications. | 2002 Mar |
|
Pseudoephedrine as a chiral auxiliary for asymmetric Michael reactions: synthesis of 3-aryl-delta-lactones. | 2002 May 30 |
|
A moderate dose of pseudoephedrine does not alter muscle contraction strength or anaerobic power. | 2002 Nov |
|
[Blood supply of the lips]. | 2002 Oct |
|
Severe adverse drug reactions due to pseudoephedrine from over-the-counter medications. | 2002 Sep |
|
Efficacy of once-daily desloratadine/pseudoephedrine for relief of nasal congestion. | 2002 Sep-Oct |
|
Pharmacokinetic interaction study of a fixed combination of 500 mg acetylsalicylic acid/30 mg pseudoephedrine versus each of the single active ingredients in healthy male volunteers. | 2003 |
|
Baboon syndrome due to pseudoephedrine. | 2003 Apr |
|
[Improving the medical treatment of minors who are victims of sexual assault or physical abuse: a receiving center and partnership between a psychiatric hospital and university hospital]. | 2003 Apr |
|
Sensitive determination of ephedrine and pseudoephedrine by capillary electrophoresis with laser-induced fluorescence detection. | 2003 Apr |
|
Nonpigmenting solitary fixed drug eruption caused by a Chinese traditional herbal medicine, ma huang (Ephedra Hebra), mainly containing pseudoephedrine and ephedrine. | 2003 Apr |
|
Physiological, subjective and performance effects of pseudoephedrine and phenylpropanolamine during endurance running exercise. | 2003 Jan |
|
Stroke associated with sympathomimetics contained in over-the-counter cough and cold drugs. | 2003 Jul |
|
Development and validation of a capillary zone electrophoresis method for the determination of ephedrine and related compounds in urine without extraction. | 2003 Jul 5 |
|
Chiral analysis of amphetamine-type stimulants using reversed-polarity capillary electrophoresis/positive ion electrospray ionization tandem mass spectrometry. | 2003 Jun |
|
[Tobacco: knowledge, reasoning and opinion of high school students in Doubs. Reflections on prevention]. | 2003 Mar |
|
In vitro evaluation of apical microleakage following canal filling with a coated carrier system compared with lateral and thermomechanical Gutta-Percha condensation techniques. | 2003 May |
|
A comparative study of root canal preparation using FlexMaster and HERO 642 rotary Ni-Ti instruments. | 2003 May |
|
Canine model of nasal congestion and allergic rhinitis. | 2003 May |
|
Exemption of chemical mixtures containing the List I chemicals ephedrine, N-methylephedrine, N-methylpseudoephedrine, norpseudoephedrine, phenylpropanolamine, and pseudoephedrine. Final rule. | 2003 May 1 |
|
Press-coating of immediate release powders onto coated controlled release tablets with adhesives. | 2003 May 20 |
Sample Use Guides
SUDAFED® 24 HOUR TABLET, EXTENDED RELEASE; ORAL (PSEUDOEPHEDRINE HYDROCHLORIDE) 240MG
adults and children 12 years and older: a tablet with water every 24 hours
children under 12 years: do not use this product in children under 12 years of age
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21631396
Curator's Comment:: Pseudoephedrine inhibits interleukin-2 (IL-2) and tumor necrosis factor (TNF) alpha-gene transcription in stimulated Jurkat cells, a human T-cell leukemia cell line.
Unknown
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Jun 26 09:17:56 UTC 2021
by
admin
on
Sat Jun 26 09:17:56 UTC 2021
|
Record UNII |
7CUC9DDI9F
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Related Record | Type |
---|
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QR01BA02
Created by
admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
|
||
|
CFR |
21 CFR 119.1
Created by
admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
|
||
|
WHO-VATC |
QR01BA52
Created by
admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
|
||
|
NDF-RT |
N0000175552
Created by
admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
|
||
|
NCI_THESAURUS |
C29709
Created by
admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
|
||
|
CFR |
21 CFR 1314.20
Created by
admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
|
||
|
WHO-ATC |
R01BA02
Created by
admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
|
||
|
LIVERTOX |
813
Created by
admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
|
||
|
NDF-RT |
N0000000209
Created by
admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
|
||
|
WHO-ATC |
R01BA52
Created by
admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
|
||
|
CFR |
21 CFR 1315.13
Created by
admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
90-82-4
Created by
admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
|
PRIMARY | |||
|
7286
Created by
admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
|
PRIMARY | |||
|
90-82-4
Created by
admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
|
PRIMARY | |||
|
SUB10157MIG
Created by
admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
|
PRIMARY | |||
|
DB00852
Created by
admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
|
PRIMARY | |||
|
8896
Created by
admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
|
PRIMARY | RxNorm | ||
|
7CUC9DDI9F
Created by
admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
|
PRIMARY | |||
|
1061
Created by
admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
|
PRIMARY | |||
|
D054199
Created by
admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
|
PRIMARY | |||
|
Pseudoephedrine
Created by
admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
|
PRIMARY | |||
|
407885
Created by
admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
|
ALTERNATIVE | |||
|
C61914
Created by
admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
|
PRIMARY | |||
|
M9294
Created by
admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
|
PRIMARY | Merck Index | ||
|
202-018-6
Created by
admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
|
PRIMARY | |||
|
CHEMBL1590
Created by
admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
|
PRIMARY | |||
|
PSEUDOEPHEDRINE
Created by
admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
|
PRIMARY | |||
|
3177
Created by
admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
|
PRIMARY | |||
|
7028
Created by
admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
|
PRIMARY | |||
|
2326
Created by
admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> INHIBITOR | |||
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR | |||
|
TARGET -> AGONIST | |||
|
SUB_CONCEPT->SUBSTANCE | |||
|
DIASTEREOISOMER -> DIASTEREOISOMER |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
MAJOR
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY | |||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||